Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Advances in non-nicotine pharmacotherapy for smoking cessation
Autore:
Covey, LS; Sullivan, MA; Johnston, JA; Glassman, AH; Robinson, MD; Adams, DP;
Indirizzi:
New York State Psychiat Inst, New York, NY 10032 USA New York State Psychiat Inst New York NY USA 10032 New York, NY 10032 USA Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA Columbia Univ Coll Phys & Surg New York NY USA 10032 w York, NY 10032 USA Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA Glaxo Wellcome Inc Res Triangle Pk NC USA 27709 Triangle Pk, NC 27709 USA Cabarrus Family Med Residency Program, Concord, NC USA Cabarrus Family MedResidency Program Concord NC USA am, Concord, NC USA E Tennessee State Univ, James Quillen Sch Med, Dept Family Med & Publ Hlth, Johnson City, TN 37614 USA E Tennessee State Univ Johnson City TN USA 37614 hnson City, TN 37614 USA
Titolo Testata:
DRUGS
fascicolo: 1, volume: 59, anno: 2000,
pagine: 17 - 31
SICI:
0012-6667(200001)59:1<17:AINPFS>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; MONOAMINE-OXIDASE-A; CIGARETTE-SMOKING; DOUBLE-BLIND; WITHDRAWAL SYMPTOMS; DEPENDENT SMOKERS; ALCOHOL DEPENDENCE; MAJOR DEPRESSION; RANDOMIZED TRIAL; BUSPIRONE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
81
Recensione:
Indirizzi per estratti:
Indirizzo: Covey, LS New York State Psychiat Inst, 1051 Riverside Dr, New York, NY 10032 USA New York State Psychiat Inst 1051 Riverside Dr New York NY USA 10032
Citazione:
L.S. Covey et al., "Advances in non-nicotine pharmacotherapy for smoking cessation", DRUGS, 59(1), 2000, pp. 17-31

Abstract

Progress in understanding the pharmacological nature of tobacco addiction,along with the modest success rates achieved by the nicotine replacement therapies, has provided the major impetus for the development of non-nicotine drugs as smoking cessation aids. This article reviews evidence from controlled trials of several non-nicotine medications for the treatment of nicotine dependence. Clonidine was the first non-nicotine medication to show efficacy for smoking cessation in multiple studies, but its effect was found to be limited atbest. Positive results across several trials have been consistent-ly demonstrated for amfebutamone (bupropion). Encouraging results have also been observed for nortriptyline and moclobemide. Studies of combined treatments using non-nicotine medications (amfebutamone, mecamylamine, oral dextrose) with nicotine replacement therapy suggest increased efficacy relative to treatments using one or the other treatment strategy alone. Thus, available evidence indicates that non-nicotine drug treatments offera promising panoply of therapeutic strategies for the addicted smoker.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 12:39:22